EA201591892A1 - Модуляторы прогестероновых рецепторов для применения в лечении фибромы матки - Google Patents

Модуляторы прогестероновых рецепторов для применения в лечении фибромы матки

Info

Publication number
EA201591892A1
EA201591892A1 EA201591892A EA201591892A EA201591892A1 EA 201591892 A1 EA201591892 A1 EA 201591892A1 EA 201591892 A EA201591892 A EA 201591892A EA 201591892 A EA201591892 A EA 201591892A EA 201591892 A1 EA201591892 A1 EA 201591892A1
Authority
EA
Eurasian Patent Office
Prior art keywords
treatment
fibroms
uterus
receptor modulators
progesteron receptor
Prior art date
Application number
EA201591892A
Other languages
English (en)
Other versions
EA030831B1 (ru
Inventor
Эльке Бештель
Иэн Остерло
Эрнест Луме
Анни Дакен
Флоранс Жан
Original Assignee
Преглем Са
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Преглем Са filed Critical Преглем Са
Publication of EA201591892A1 publication Critical patent/EA201591892A1/ru
Publication of EA030831B1 publication Critical patent/EA030831B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/36—Antigestagens
    • H—ELECTRICITY
    • H05—ELECTRIC TECHNIQUES NOT OTHERWISE PROVIDED FOR
    • H05K—PRINTED CIRCUITS; CASINGS OR CONSTRUCTIONAL DETAILS OF ELECTRIC APPARATUS; MANUFACTURE OF ASSEMBLAGES OF ELECTRICAL COMPONENTS
    • H05K9/00—Screening of apparatus or components against electric or magnetic fields
    • H05K9/0007—Casings
    • H05K9/0052—Shielding other than Faraday cages

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microelectronics & Electronic Packaging (AREA)
  • Power Engineering (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Gynecology & Obstetrics (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Percussion Or Vibration Massage (AREA)

Abstract

Настоящее изобретение относится к долгосрочной терапии, включающей повторные курсы лечения улипристала ацетатом или любым его метаболитом с целью лечения фибромы матки. Настоящее изобретение также относится к комбинированной терапии с применением улипристала ацетата с прогестином для повышения эффективности используемого в настоящее время лечения фибромы матки.
EA201591892A 2013-04-10 2014-04-09 Способ лечения фибромы матки EA030831B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
HUP1300211 2013-04-10
PCT/IB2014/060558 WO2014167510A2 (en) 2013-04-10 2014-04-09 Progesteron receptor modulators for use in the therapy of uterine fibroids

Publications (2)

Publication Number Publication Date
EA201591892A1 true EA201591892A1 (ru) 2016-02-29
EA030831B1 EA030831B1 (ru) 2018-10-31

Family

ID=89707373

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201591892A EA030831B1 (ru) 2013-04-10 2014-04-09 Способ лечения фибромы матки

Country Status (19)

Country Link
US (2) US10172869B2 (ru)
EP (1) EP2983672A2 (ru)
JP (1) JP2016516764A (ru)
KR (1) KR20150139919A (ru)
CN (1) CN105120874A (ru)
AR (1) AR095831A1 (ru)
AU (1) AU2014252196B2 (ru)
BR (1) BR112015025954A2 (ru)
CA (1) CA2907674A1 (ru)
EA (1) EA030831B1 (ru)
HK (1) HK1221169A1 (ru)
IL (1) IL241380B (ru)
MX (1) MX2015014199A (ru)
MY (1) MY181448A (ru)
NZ (1) NZ712984A (ru)
SG (1) SG11201507260QA (ru)
UY (1) UY35528A (ru)
WO (1) WO2014167510A2 (ru)
ZA (1) ZA201507535B (ru)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA036237B1 (ru) * 2015-05-18 2020-10-16 Байер Фарма Акциенгезельшафт Режим приема селективного модулятора рецептора прогестерона (sprm)

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3545439A (en) 1968-01-04 1970-12-08 Upjohn Co Medicated devices and methods
US3920805A (en) 1971-12-09 1975-11-18 Upjohn Co Pharmaceutical devices and method
US4155991A (en) 1974-10-18 1979-05-22 Schering Aktiengesellschaft Vaginal ring
IL48277A (en) 1974-10-18 1978-03-10 Schering Ag Vaginal ring
US3991760A (en) 1975-12-02 1976-11-16 The Procter & Gamble Company Vaginal medicament dispensing means
US3995633A (en) 1975-12-02 1976-12-07 The Procter & Gamble Company Vaginal Medicament dispensing device
US3995634A (en) 1975-12-02 1976-12-07 The Procter & Gamble Company Vaginal cavity dispensing means and method
US4286587A (en) 1978-10-11 1981-09-01 Alza Corporation Vaginal drug delivery system made from polymer
US4292965A (en) 1978-12-29 1981-10-06 The Population Council, Inc. Intravaginal ring
US4250611A (en) 1979-04-19 1981-02-17 Alza Corporation Process for making drug delivery device with reservoir
EP0180264A1 (en) 1984-10-12 1986-05-07 Akzo N.V. Release system for two or more active substances
NL8500470A (nl) 1985-02-19 1986-09-16 Achel Homesteel Pvba Intravaginaal orgaan.
US4954490A (en) 1988-06-23 1990-09-04 Research Triangle Institute 11 β-substituted progesterone analogs
FI95768C (fi) 1993-06-17 1996-03-25 Leiras Oy Emättimensisäinen antosysteemi
US5929262A (en) 1995-03-30 1999-07-27 The United States Of America As Represented By The Department Of Health And Human Services Method for preparing 17α-acetoxy-11β-(4-N, N-dimethylaminophyl)-19-Norpregna-4,9-diene-3, 20-dione, intermediates useful in the method, and methods for the preparation of such intermediates
US5972372A (en) 1996-07-31 1999-10-26 The Population Council, Inc. Intravaginal rings with insertable drug-containing core
FR2827517B1 (fr) 2001-07-23 2003-10-24 Bioalliance Pharma Systemes therapeutiques bioadhesifs a liberation prolongee
ES2212912B1 (es) 2003-01-22 2005-10-01 Crystal Pharma, S.A. Procedimiento para la obtencion de 17alfa-acetoxi-11beta-(4-n,n-dimetilaminofenil)-19-norpregna-4,9-dien-3,20-diona.
JP2006519255A (ja) 2003-02-28 2006-08-24 アメリカ合衆国 １７α−アセトキシ−１１β−（４−Ｎ，Ｎ−ジメチルアミノフェニル）−１９−ノルプレグナ−４，９−ジエン−３，２０−ジオンの製造方法、その中間体及びそのような中間体の製造方法
US20050215536A1 (en) 2004-03-24 2005-09-29 Kristof Chwalisz Sequential SPRM/ progestin treatment
US20050215535A1 (en) 2004-03-24 2005-09-29 Kristof Chwalisz Sequential SPRM/progestin treatment
EP1768625B1 (en) 2004-07-09 2011-02-09 The Population Council, Inc. Sustained release compositions containing progesterone receptor modulators
WO2007103510A2 (en) 2006-03-08 2007-09-13 Danco Laboratories Llc Methods, dosing regimens & medications using anti-progestational agents for the treatment of disorders
SI3263112T1 (sl) 2006-10-24 2020-10-30 Allergan Pharmaceuticals International Limited Sestavki in metode za zaviranje endometrijskih proliferacij
TW200831110A (en) 2006-12-28 2008-08-01 Repros Therapeutics Inc Methods and formulations for improved bioavailability of antiprogestins
US8299050B2 (en) * 2008-01-29 2012-10-30 Laboratoire Hra-Pharma Method for treating uterine fibroids
US8512745B2 (en) * 2008-12-08 2013-08-20 Laboratoire Hra Pharma Ulipristal acetate tablets
CN102727457B (zh) * 2011-04-08 2014-05-28 华润紫竹药业有限公司 稳定的醋酸优力司特制剂

Also Published As

Publication number Publication date
KR20150139919A (ko) 2015-12-14
AU2014252196A1 (en) 2015-10-29
IL241380B (en) 2018-11-29
CN105120874A (zh) 2015-12-02
CA2907674A1 (en) 2014-10-16
UY35528A (es) 2014-09-30
US10172869B2 (en) 2019-01-08
NZ712984A (en) 2020-07-31
US20190262361A1 (en) 2019-08-29
US20160038510A1 (en) 2016-02-11
AU2014252196B2 (en) 2019-05-16
JP2016516764A (ja) 2016-06-09
EA030831B1 (ru) 2018-10-31
WO2014167510A3 (en) 2015-02-19
ZA201507535B (en) 2017-02-22
MX2015014199A (es) 2016-06-21
MY181448A (en) 2020-12-22
SG11201507260QA (en) 2015-10-29
WO2014167510A2 (en) 2014-10-16
EP2983672A2 (en) 2016-02-17
HK1221169A1 (zh) 2017-05-26
IL241380A0 (en) 2015-11-30
BR112015025954A2 (pt) 2017-07-25
AR095831A1 (es) 2015-11-11

Similar Documents

Publication Publication Date Title
DOP2017000078A (es) Indazoles sustituidos con bencilo como inhibidores de bub1.
BR112016002391A2 (pt) composições tópicas e métodos de uso das mesmas
DK3498725T3 (da) 19-nor c3,3-desubstitueret c21-n-pyrazolyl steroid til anvendelse i terapi
MX2016003129A (es) Terapia de combinacion de anticuerpos contra el csf-1r humano y anticuerpos contralel pd-l1 humano.
PH12016502167A1 (en) Hdl theraphy markers
PH12015502161A1 (en) Therapeutic compounds and compositions
EA201491009A1 (ru) Гель лизата тромбоцитов
PH12015501071A1 (en) Combination therapy of anti-her3 antibodies
ECSP16012582A (es) Compuestos heterocíclicos y métodos de uso
BR112015030387A2 (pt) compostos de pirazol como moduladores de fshr e usos dos mesmos
CL2017001135A1 (es) Anticuerpos mejorados contra il-6
MX2016000158A (es) Dispositivo de oclusion con canal con posibilidad de apertura.
CU20160051A7 (es) Sistema de administración intrauterina
DK201300055U4 (da) Tæppe med kanaler fyldt med i det væsentlige sfæriske objekter til terapeutisk behandling
EP2985029A4 (en) MEDICATION FOR EXTERNAL USE IN CLEANING AND CARE OF OVARIES, VAGS AND VULVES
MX2016004389A (es) Dispositivo de calentamiento novedoso.
EA201591892A1 (ru) Модуляторы прогестероновых рецепторов для применения в лечении фибромы матки
BR112014030406A8 (pt) combinação de canabidiol fitocanabinoide com hipotermia terapêutica, e, uso de uma combinação
ES1090031Y (es) Dispositivo terapéutico y anticonceptivo de uso vaginal
BR112015016741A2 (pt) composição, dispositivo e sistema
AR111715A1 (es) ANTICUERPOS ANTI-SIRPa
CL2015003211A1 (es) Combinación sinergística de paracetamol/celecoxib para el tratamiento de dolor inflamatorio.
HK1205000A1 (en) Intrauterine application of 18-methyl-15ss,16ss-methylene-19-nor-20- spirox-4-en-3-one systems, intrauterine systems containing 18-methyl- 15ss,16ss-methylene-19-nor-20-spirox-4-en-3-one, as well as the use thereof in contraception and gynaecological therapy 18--1516--19--20--4--3- 18--1516--19--20--4--3-
EA201491939A1 (ru) Модуляторы прогестероновых рецепторов для применения в профилактике или лечении болезней, опосредованных андрогенами
IN2013MU02732A (ru)